{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:04:38Z","timestamp":1787943878873,"version":"build-2784847793"},"reference-count":134,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The use of the BCL2 inhibitor venetoclax in combination with hypomethylating agents (HMA) is a revolution for the treatment of frail and elderly acute myeloid leukemia (AML) patients. This effective treatment strategy is increasingly more and more applicable for other subsets of AML patients and is currently being tested in numerous clinical trials in combination with other drugs in all treatment lines. In particular, venetoclax combinations can also serve as a definitive therapy or as an effective bridge to allogeneic hematopoietic stem cell transplantation (HSCT). However, the factors affecting response to venetoclax in the abovementioned AML patients are not completely clear and understood until today. The aim of this review is to describe the molecular and clinical patterns of response and durable remission of venetoclax-based combinations in AML patients. Hence, mutations in IDH1, IDH2, ASXL1, NPM1, DDX41, chromatin-cohesin complex and splicing-factor genes predict superior response to venetoclax, while inferior response to the drug has been observed for FLT3-ITD, KRAS, NRAS and TP53 gene mutations. Intriguingly, the achievement of measurable residual disease (MRD) negativity in the first four cycles of venetoclax administration characterizes a subgroup of NPM1-mutated AML patients with a more favorable outcome. Even though focus will be given on factors influencing response to the drug in this review, the main mechanisms of resistance to venetoclax in AML patients will also be discussed.<\/jats:p>","DOI":"10.3389\/fonc.2025.1577908","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:13:16Z","timestamp":1757909596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Factors affecting response and resistance to venetoclax in acute myeloid leukemia"],"prefix":"10.3389","volume":"15","author":[{"given":"Michael D.","family":"Diamantidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158518","article-title":"Long-term follow-up of the phase 3 viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy","volume":"140","author":"Pratz","year":"2022","journal-title":"Blood (ASH Annu Meeting Abstracts)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal hscs determines chemotherapeutic success in aml","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug resistance (Alhambra Calif)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584974","article-title":"Targeting bcl-2 proteins in acute myeloid leukemia","volume":"10","author":"Wei","year":"2020","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.896426","article-title":"Drug resistance mechanisms of acute myeloid leukemia stem cells","volume":"12","author":"Niu","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1501950","article-title":"Bcl-2 inhibitors in hematological Malignancies: biomarkers that predict response and management strategies","volume":"14","author":"Markouli","year":"2024","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215096","article-title":"Bcl-2 Expression in Aml Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies","volume":"10","author":"Tiribelli","year":"2021","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of bcl-2 family inhibitors abt-199 and abt-737 combined with 5-azacytidine in myeloid Malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and bcl-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in aml through activation of the integrated stress response","volume":"11","author":"Sharon","year":"2019","journal-title":"Sci Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1900","article-title":"5-azacitidine induces noxa to prime aml cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/hematolrep15010010","article-title":"Synergistic interactions between the hypomethylating agent thio-deoxycytidine and venetoclax in myelodysplastic syndrome cells","volume":"15","author":"Hu","year":"2023","journal-title":"Hematol Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28091","article-title":"The bcl-2 inhibitor venetoclax inhibits nrf2 antioxidant pathway activation induced by hypomethylating agents in aml","volume":"234","author":"Nguyen","year":"2019","journal-title":"J Cell Physiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1158\/2767-9764.Crc-22-0259","article-title":"Combination of a new oral demethylating agent, or2100, and venetoclax for treatment of acute myeloid leukemia","volume":"3","author":"Kamachi","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and idh1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with aml","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02246-2","article-title":"Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia","volume":"38","author":"Fruchtman","year":"2024","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with aml treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed idh1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in idh1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce bcl-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to idh mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J Exp Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-320937","article-title":"Differential prognosis impact of idh2 mutations in cytogenetically normal acute myeloid leukemia","volume":"117","author":"Boissel","year":"2011","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of idh2 mutations in aml depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and prognostic impact of idh mutations in aml: A cog, swog, and ecog analysis","volume":"7","author":"Zarnegar-Lumley","year":"2023","journal-title":"Blood Adv"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"New Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical outcomes associated with npm1 mutations in patients with relapsed or refractory aml","volume":"7","author":"Issa","year":"2023","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016963","article-title":"Long-term follow-up of viale-C in patients with untreated aml ineligible for intensive chemotherapy","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000912","article-title":"Bcl2 inhibition: A new paradigm for the treatment of aml and beyond","volume":"7","author":"Wei","year":"2023","journal-title":"Hemasphere"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (Caveat): A phase ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014900","article-title":"Final analysis of the phase 1b chemotherapy and venetoclax in elderly acute myeloid leukemia trial (Caveat)","volume":"9","author":"Chua","year":"2025","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7150\/jca.16010","article-title":"Nucleophosmin mutations induce chemosensitivity in thp-1 leukemia cells by suppressing nf-Kb activity and regulating bax\/bcl-2 expression","volume":"7","author":"Zhang","year":"2016","journal-title":"J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043161","article-title":"Targeting and monitoring acute myeloid leukaemia with nucleophosmin-1 (Npm1) mutation","volume":"24","author":"Chin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s1097-2765(01)00320-3","article-title":"Bcl-2, bcl-X(L) sequester bh3 domain-only molecules preventing bax- and bak-mediated mitochondrial apoptosis","volume":"8","author":"Cheng","year":"2001","journal-title":"Mol Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-13-0609","article-title":"Selective bcl-2 inhibition by abt-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031421","article-title":"Biomarkers of response to venetoclax therapy in acute myeloid leukemia","volume":"25","author":"Rodr\u00edguez-Medina","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-09-0878","article-title":"Blockade of mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase and murine double minute synergistically induces apoptosis in acute myeloid leukemia via bh3-only proteins puma and bim","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1002\/ajh.26057","article-title":"Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia","volume":"96","author":"Arslan","year":"2021","journal-title":"Am J Hematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41408-023-00928-1","article-title":"Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: A cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of aml in adults: 2022 recommendations from an international expert panel on behalf of the eln","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169509","article-title":"Eln risk stratification is not predictive of outcomes for treatment-naive ptients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021579","article-title":"Molecular mrd is strongly prognostic in patients with npm1-mutated aml receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011106","article-title":"Venetoclax-based low intensity therapy in molecular failure of npm1-mutated aml","volume":"8","author":"Jimenez-Chillon","year":"2024","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with aml receiving less-intensive therapies: the 2024 eln recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients","volume":"99","author":"Gangat","year":"2024","journal-title":"Am J Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid Malignancies and ddx41 variants","volume":"98","author":"Bataller","year":"2023","journal-title":"Am J Hematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13581","article-title":"Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia","volume":"293","author":"Weng","year":"2023","journal-title":"J Intern Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41408-021-00541-0","article-title":"Asxl1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine","volume":"11","author":"Rahmani","year":"2021","journal-title":"Blood Cancer J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02230-w","article-title":"Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed aml patients","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-22-0939","article-title":"Combinatorial bcl2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-16-0313","article-title":"Efficacy and biological correlates of response in a phase ii study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"B60","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225608","article-title":"Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance","volume":"13","author":"Garciaz","year":"2021","journal-title":"Cancers"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061091","article-title":"Venetoclax resistance in acute myeloid leukemia","volume":"16","author":"Garciaz","year":"2024","journal-title":"Cancers"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2021.101251","article-title":"Mechanisms for resistance in aml insights into molecular pathways mediating resistance to venetoclax","volume":"34","author":"Konopleva","year":"2021","journal-title":"Best Pract Res Clin haematology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08137-x","article-title":"Ras-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2643-3230.Bcd-24-0235","article-title":"The crossroads of clonal evolution, differentiation hierarchy, and ontogeny in leukemia development","volume":"6","author":"Sturgeon","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"B67","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of ras\/mapk pathway confers mcl-1 mediated acquired resistance to bcl-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am J Hematol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091586","article-title":"Unraveling venetoclax resistance: navigating the future of hma\/venetoclax-refractory aml in the nolecular era","volume":"17","author":"Chatzilygeroudi","year":"2025","journal-title":"Cancers"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/19336918.2017.1393591","article-title":"Myeloid cell leukemia 1 (Mcl-1), an unexpected modulator of protein kinase signaling during invasion","volume":"12","author":"Young","year":"2018","journal-title":"Cell Adh Migr"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-19-0125","article-title":"The tp53 apoptotic network is a primary mediator of resistance to bcl2 inhibition in aml cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010167","article-title":"Intact tp-53 function is essential for sustaining durable responses to bh3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of tp53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers bcl-xl dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115759","article-title":"Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: in vitro models and mechanisms","volume":"216","author":"Carter","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of abt-199 sensitivity in human aml","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-3057","article-title":"Binding of released bim to mcl-1 is a mechanism of intrinsic resistance to abt-199 which can be overcome by combination with daunorubicin or cytarabine in aml cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Genes Dev"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1172\/jci39964","article-title":"Mcl1 haploinsufficiency protects mice from myc-induced acute myeloid leukemia","volume":"120","author":"Xiang","year":"2010","journal-title":"J Clin Invest"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19314","article-title":"Venetoclax resistance in acute myeloid leukaemia-clinical and biological insights","volume":"204","author":"Nachmias","year":"2024","journal-title":"Br J haematology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2429604","article-title":"Bcl-2 inhibition in acute myeloid leukemia: resistance and combinations","volume":"17","author":"Tatarata","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/181145","article-title":"Mechanisms of resistance to venetoclax in hematologic Malignancies","volume":"33","author":"Zielonka","year":"2024","journal-title":"Adv Clin Exp Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1005659","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/srep27696","article-title":"Targeting mcl-1\/bcl-xl forestalls the acquisition of resistance to abt-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048","article-title":"Abt-199, a potent and selective bcl-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0306-6","article-title":"Targeting bax to drug death directly","volume":"15","author":"Walensky","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using bh3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014446","article-title":"Acquired bcl2 variants associated with venetoclax resistance in acute myeloid leukemia","volume":"9","author":"Brown","year":"2025","journal-title":"Blood Adv"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in bax confer resistance to bh3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01879-z","article-title":"Targeting a mitochondrial E3 ubiquitin ligase complex to overcome aml cell-intrinsic venetoclax resistance","volume":"37","author":"Nakao","year":"2023","journal-title":"Leukemia"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/path.4774","article-title":"In brief: mitophagy: mechanisms and role in human disease","volume":"240","author":"Springer","year":"2016","journal-title":"J Pathol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-22-0601","article-title":"Mitophagy promotes resistance to bh3 mimetics in acute myeloid leukemia","volume":"13","author":"Glytsou","year":"2023","journal-title":"Cancer Discov"},{"key":"B94","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.Cd-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"key":"B95","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.648407","article-title":"Clinically-relevant abc transporter for anti-cancer drug resistance","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Pharmacol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1038\/s41467-023-41229-2","article-title":"Abcc1 and glutathione metabolism limit the efficacy of bcl-2 inhibitors in acute myeloid leukemia","volume":"14","author":"Ebner","year":"2023","journal-title":"Nat Commun"},{"key":"B100","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in understanding the mechanisms of resistance to bcl-2 inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo6891","article-title":"The path to venetoclax resistance is paved with mutations, metabolism, and more","volume":"14","author":"Sullivan","year":"2022","journal-title":"Sci Transl Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16233974","article-title":"Inflammation and related signaling pathways in acute myeloid leukemia","volume":"16","author":"Naji","year":"2024","journal-title":"Cancers"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of ifn\u03b3 Signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/nature19830","article-title":"The mcl1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"B105","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of mcl-1-specific inhibitor azd5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0387","article-title":"Amg 176, a selective mcl1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting mcl-1 in hematologic Malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22284","article-title":"Combined venetoclax and alvocidib in acute myeloid leukemia","volume":"8","author":"Bogenberger","year":"2017","journal-title":"Oncotarget"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3159","article-title":"A phase 1b study of venetoclax and alvocidib in patients with relapsed\/refractory acute myeloid leukemia","volume":"41","author":"Jonas","year":"2023","journal-title":"Hematological Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-15-1070","article-title":"The cdk9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of mll-rearranged acute myeloid leukemia","volume":"76","author":"Baker","year":"2016","journal-title":"Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01754","article-title":"Discovery of azd4573, a potent and selective inhibitor of cdk9 that enables short duration of target engagement for the treatment of hematological Malignancies","volume":"63","author":"Barlaam","year":"2020","journal-title":"J Med Chem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1853","article-title":"Azd4573 is a highly selective cdk9 inhibitor that suppresses mcl-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-447441","article-title":"Targeting acute myeloid leukemia by dual inhibition of pi3k signaling and cdk9-mediated mcl-1 transcription","volume":"122","author":"Thomas","year":"2013","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2019.03.046","article-title":"Inhibition of usp9x induces apoptosis in flt3-itd-positive aml cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress","volume":"453","author":"Akiyama","year":"2019","journal-title":"Cancer Lett"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013277","article-title":"Ceramide-induced integrated stress response overcomes bcl-2 inhibitor resistance in acute myeloid leukemia","volume":"139","author":"Lewis","year":"2022","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-720433","article-title":"Targeting sphingosine kinase 1 induces mcl1-dependent cell death in acute myeloid leukemia","volume":"129","author":"Powell","year":"2017","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-859405","article-title":"Humanized mcl-1 mice enable accurate preclinical evaluation of mcl-1 inhibitors destined for clinical use","volume":"132","author":"Brennan","year":"2018","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1101\/gad.215871.113","article-title":"Loss of mcl-1 leads to impaired autophagy and rapid development of heart failure","volume":"27","author":"Thomas","year":"2013","journal-title":"Genes Dev"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of mcl-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Genes Dev"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of viale-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19325","article-title":"Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax\u2009+\u2009Hypomethylating agents","volume":"204","author":"Johnson","year":"2024","journal-title":"Br J haematology"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus ldac for newly diagnosed aml ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with idh2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199170","article-title":"Ziftomenib combined with venetoclax\/azacitidine in relapsed\/refractory npm1-M or kmt2a-R acute myeloid leukemia: interim phase 1a results from komet-007","volume":"144","author":"Fathi","year":"2024","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/jco.24.00826","article-title":"Menin inhibition with revumenib for kmt2a-rearranged relapsed or refractory acute leukemia (Augment-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-024-01054-2","article-title":"Ras mutations in myeloid Malignancies: revisiting old questions with novel insights and therapeutic perspectives","volume":"14","author":"Alawieh","year":"2024","journal-title":"Blood Cancer J"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1159\/000525566","article-title":"A phase ii study of azacitidine, venetoclax, and trametinib in relapsed or refractory acute myeloid leukemia harboring ras pathway-activating mutations","volume":"145","author":"Desikan","year":"2022","journal-title":"Acta haematologica"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.007","article-title":"Venetoclax and cobimetinib in relapsed\/refractory aml: A phase 1b trial","volume":"24","author":"Konopleva","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory aml: A nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2023","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT225","article-title":"Aaron: an ongoing open-label phase I\/ii study of relatlimab (Anti-lag-3) with nivolumab (Anti-pd-1) in combination with azacitidine \u00b1 Venetoclax for the treatment of patients with relapsed\/refractory and non-fit patients with newly diagnosed acute myeloid leukemia - interim analysis","volume":"85","author":"Buecklein","year":"2025","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-Mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186699","article-title":"Phase I\/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML","volume":"142","author":"Yilmaz","year":"2023","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A Phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-Mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202620","article-title":"Phase II study of cladribine with low dose cytarabine and venetoclax alternating with azacytidine and venetoclax for newly diagnosed acute myeloid leukemia","volume":"144","author":"Bataller","year":"2024","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1577908\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:13:17Z","timestamp":1757909597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1577908\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":134,"alternative-id":["10.3389\/fonc.2025.1577908"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1577908","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"article-number":"1577908"}}